AH-7921 (3,4- dichloro -N-[(1- dimethylamino) cyclohexylmethyl] benzamide) is an opioid analgesic drug selective for the µ-opioid receptor, having around 80% the potency of morphine when administered orally. It was discovered in the 1970s by a team at Allan and Hanbury's. AH 7921 is an N-substituted cyclohexylmethylbenzamide classified as an opioid analgesic with high addictive liability. It acts as a selective µ-opioid receptor agonistMinimal oral effective doses for complete pain suppression by AH 7921 are 1.25 and 13.8 mg/kg for canine and rhesus monkey, respectively. In the mouse, AH 7921 has the highest affinity for the EP2 receptor, but also acts as a weak ligand at the murine EP1 and DP1 receptorsIn whole human platelets, AH 7921 is an effective antagonist of the antiaggregatory actions. Till date five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal product
A trivial name(s) doxylam has been proposed for this compound, but it has never been never sold commercially for medical use. In 2013 AH-7921 was discovered to have been used as an active ingredient in "synthetic cannabis" products in Japan.